| Product name | PAR14 Polyclonal Antibody |
| Immunogen | Synthesized peptide derived from part region of human PAR14 protein |
| Host | Rabbit |
| Reactivity | Human,Mouse |
| Applications | WB,ELISA |
| Applications notes | Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000;ELISA 1:5000-20000 |
| Clonality | Polyclonal |
| Preparation method | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Alternative | ADP-ribosyltransferase diphtheria toxin-like 8; B aggressive lymphoma protein 2 |
| Formulation | Liquid solution |
| Concentration | 1 mg/ml |
| Molecular weight | 198kD |
| Storage buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA |
| Storage instructions | Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing. |
| Shipping | Gel pack with blue ice. |
| Precautions | The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product. |
| Background | PARP14 encodes a member of the poly(ADP-ribose) polymerase (PARP) protein family. The encoded anti-apoptotic protein may regulate aerobic glycolysis and promote survival of cancer cells. Increased expression of PARP14 has been reported in a variety of tumor types. |
| Gene ID | 54625 |
| Alternative | ADP-ribosyltransferase diphtheria toxin-like 8; B aggressive lymphoma protein 2 |
| Others | The antibody detects endogenous levels of PAR14 protein |
| Accession | Q460N5 |
| Observed Band(KD) | 198 |
You must be logged in to post a review.
Reviews
There are no reviews yet.